Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use TABRECTA safely and effectively. See full prescribing information for TABRECTA. TABRECTA® (capmatinib) tablets, for oral use Initial U.S. Approval: 2020
Medication labelWhy this: Advisory · dailymed-prescription
TABRECTA is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test.
- generic_name
- capmatinib
- product_names
- capmatinib
- ndc
- 0078-0709, 0078-0709-56, 0078-0709-94, 0078-0716, 0078-0716-56, 0078-0716-94
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en